


# 3<sup>rd</sup> International Conference on **Virology, Infectious Diseases and COVID-19**

October 24-25, 2022/ Holiday Inn Express Dubai - Safa Park, an IHG Hotel



**Prof. D. Kyoung Seob Song**

**Kyoung Seob Song\* and Hyun-Chae Lee**

*Department of Medical Science, Kosin University College of Medicine, Busan 49267, Korea*

## **Effects of PDZ domain of ZO-1 on *Pseudomonas aeruginosa* LPS-activated inflammation in the airway.**

**P***seudomonas aeruginosa* has been known as an important pathogen in many human diseases. Therefore, examining the negative control mechanisms of tight junction protein ZO-1 on the exotoxin LPS of *P. aeruginosa*-induced diseases could be critical in the development of novel therapeutics. We found that ZO-1 expression dramatically decreased in inflammatory human lung tissues. Interestingly, PDZ1 deletion of the PDZ domain in the ZO-1 protein dramatically decreased LPS-induced F-actin formation and increased the expression of genes for pro-inflammatory cytokines, but not PDZ2 and PDZ3 of the ZO-1 protein. We also found that the consensus PDZ peptide (based on PDZ1) of ZO-1 down-regulates the expression of pro-inflammatory cytokine genes and F-actin formation; in contrast, the GG24,25AA mutant PDZ peptide cannot control these genes. LPS activates IL-8 secretion extracellularly in a time-dependent manner, while the secretion is inhibited by PDZ peptide. Whereas increased IL-8 secretion by LPS activates the CXCR2 receptor, overexpressed RGS12 negatively regulates LPS-induced CXCR2/IL-8 signaling. The PDZ peptide also decreases LPS-induced inflammatory cell populations, pro-inflammatory cytokine gene expression, and TEER in bronchoalveolar lavage fluid and cultured alveolar macrophages. Collectively, we suggest that the PDZ peptide may be a potential therapeutic for bacteria-induced respiratory diseases.

**Keywords:** LPS, ZO-1, proinflammatory cytokine, PDZ, IL-8, airway inflammation